<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med. Genet</journal-id><journal-title-group><journal-title>BMC Medical Genetics</journal-title></journal-title-group><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22978414</article-id><article-id pub-id-type="pmc">3495049</article-id><article-id pub-id-type="publisher-id">1471-2350-13-82</article-id><article-id pub-id-type="doi">10.1186/1471-2350-13-82</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><italic>PNPLA 3</italic> I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="A1"><name><surname>Rembeck</surname><given-names>Karolina</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>karolinarembeck@gmail.com</email></contrib><contrib contrib-type="author" equal-contrib="yes" id="A2"><name><surname>Maglio</surname><given-names>Cristina</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>cristina.maglio@wlab.gu.se</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Lagging</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>martin.lagging@medfak.gu.se</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Christensen</surname><given-names>Peer Brehm</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>peer.christensen@dadlnet.dk</email></contrib><contrib contrib-type="author" id="A5"><name><surname>F&#x000e4;rkkil&#x000e4;</surname><given-names>Martti</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>martti.farkkila@hus.fi</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Langeland</surname><given-names>Nina</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>nina.langeland@mofa.uib.no</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Buhl</surname><given-names>Mads Rauning</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>madsbuhl@rm.dk</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Pedersen</surname><given-names>Court</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>Court.Pedersen@ouh.regionsyddanmark.dk</email></contrib><contrib contrib-type="author" id="A9"><name><surname>M&#x000f8;rch</surname><given-names>Kristine</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>kristine.morch@helse-bergen.no</email></contrib><contrib contrib-type="author" id="A10"><name><surname>Norkrans</surname><given-names>Gunnar</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>gunnar.norkrans@vgregion.se</email></contrib><contrib contrib-type="author" id="A11"><name><surname>Hellstrand</surname><given-names>Kristoffer</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>kristoffer.hellstrand@microbio.gu.se</email></contrib><contrib contrib-type="author" id="A12"><name><surname>Lindh</surname><given-names>Magnus</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>magnus.lindh@microbio.gu.se</email></contrib><contrib contrib-type="author" id="A13"><name><surname>Pirazzi</surname><given-names>Carlo</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>carlo.pirazzi@wlab.gu.se</email></contrib><contrib contrib-type="author" id="A14"><name><surname>Burza</surname><given-names>Maria Antonella</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>Maria-Antonella.Burza@wlab.gu.se</email></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="A15"><name><surname>Romeo</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>stefano.romeo@wlab.gu.se</email></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="A16"><name><surname>Westin</surname><given-names>Johan</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>johan.westin@gu.se</email></contrib><on-behalf-of>for the NORDynamIC group<xref ref-type="corresp" rid="d33e151"/></on-behalf-of></contrib-group><aff id="I1"><label>1</label>Department of Infectious Diseases/Virology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden</aff><aff id="I2"><label>2</label>Department of Molecular and Clinical Medicine and Center for Cardiovascular and Metabolic Research, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden</aff><aff id="I3"><label>3</label>Department of Infectious Diseases, University of Southern Denmark, Odense, Denmark</aff><aff id="I4"><label>4</label>Department of Gastroenterology, Helsinki University, Helsinki, Finland</aff><aff id="I5"><label>5</label>Department of Medicine, Haukeland University Hospital and Institute of Medicine, University of Bergen, Bergen, Norway</aff><aff id="I6"><label>6</label>Department of Infectious Diseases, Aarhus University, Aarhus, Denmark</aff><author-notes><corresp id="d33e151">for the NORDynamIC group</corresp></author-notes><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>14</day><month>9</month><year>2012</year></pub-date><volume>13</volume><fpage>82</fpage><lpage>82</lpage><history><date date-type="received"><day>27</day><month>3</month><year>2012</year></date><date date-type="accepted"><day>20</day><month>6</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2012 Rembeck et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Rembeck et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2350/13/82"/><abstract><sec><title>Background</title><p>Hepatic steatosis in HCV patients has been postulated as a risk factor associated with a higher frequency of fibrosis and cirrhosis. A single genetic variant, <italic>PNPLA3</italic> I148M, has been widely associated with increased hepatic steatosis. Previous studies of the <italic>PNPLA3</italic> I148M sequence variant in HCV infected individuals have reported an association between this variant and prevalence of steatosis, fibrosis, and cirrhosis. To evaluate the impact of <italic>PNPLA3</italic> I148M variant on metabolic traits and treatment response in HCV genotype 2 and 3 infected patients.</p></sec><sec><title>Methods</title><p>Three hundred and eighty-two treatment na&#x000ef;ve HCV genotype 2 or 3 infected patients were included in a phase III, open label, randomized, multicenter, investigator-initiated trial (the NORDynamIC study), in which pretreatment liver biopsies were mandatory. <italic>PNPLA3I148M</italic> genotyping was performed in a total of 359 Caucasian patients.</p></sec><sec><title>Results</title><p>In HCV genotype 2 infected patients carrying the <italic>PNPLA3</italic> 148M allele, there was significantly increased insulin resistance (P&#x02009;=&#x02009;0.023) and lower viral load (P&#x02009;=&#x02009;0.005) at baseline as well as the first seven days of antiviral treatment. These results were not observed in HCV genotype 3 infected patients.</p></sec><sec><title>Conclusions</title><p>Our results suggest a possible association between the <italic>PNPLA3</italic> 148M allele and insulin resistance as well as baseline viral load in HCV genotype 2, but not in genotype 3.</p></sec></abstract><kwd-group><kwd>Hepatitis C</kwd><kwd><italic>PNPLA 3</italic></kwd><kwd>Insulin resistance</kwd><kwd>Viral load</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Chronic hepatitis C virus (HCV) infection is a major cause of cirrhosis and liver failure [<xref ref-type="bibr" rid="B1">1</xref>]. Hepatic steatosis is twice as common in HCV infected patients as in the normal population [<xref ref-type="bibr" rid="B2">2</xref>] and it is associated with fibrosis and cirrhosis development [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. Metabolic host factors, mainly obesity, insulin resistance and type 2 diabetes, are thought to play an important role in the steatosis development in non&#x02013;genotype 3 infected individuals, whereas HCV genotype 3-associated hepatic steatosis appears to mainly result from a direct viral action [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B6">6</xref>].</p><p>A single genetic variant, I148M, entailing a change from isoleucine (I) to methionine (M) at position 148 in the human patatin-like phospholipase domain containing 3 gene (<italic>PNPLA3</italic>, Adiponutrin) on chromosome 22 has been widely associated with increased hepatic steatosis [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B11">11</xref>]. Recently, in a murine model, <italic>PNPLA3</italic> was found to be involved in the hepatic metabolism of triglycerides and in the regulation of systemic glucose homeostasis [<xref ref-type="bibr" rid="B12">12</xref>]. Even if previous reports failed to find an association with insulin resistance assessed by euglycemic hyperinsulinemic clamp or surrogates in humans [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B15">15</xref>], a recent study reported that <italic>PNPLA3</italic> I148M variant is associated with insulin resistance in a normoglycaemic population from Taiwan [<xref ref-type="bibr" rid="B16">16</xref>]. Furthermore, the <italic>PNPLA3</italic> 148M allele genetic variant was found to be associated with lower serum triglyceride and higher fasting glucose levels in individuals with gallstones [<xref ref-type="bibr" rid="B17">17</xref>]. In the setting of HCV infection, <italic>PNPLA3</italic> I148M sequence variant has been extensively associated with steatosis, fibrosis progression, cirrhosis and hepatocellular carcinoma [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B21">21</xref>]. So far, no association has been reported between the <italic>PNPLA3</italic> I148M variant and insulin resistance or triglyceride levels in individuals with HCV infection [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B20">20</xref>].</p><p>The aim of the present study was to examine the impact of <italic>PNPLA3</italic> I148M variant on metabolic traits and treatment response in a well phenotyped HCV genotype 2 and 3 cohort, within the framework of the NORDynamIC treatment trial [<xref ref-type="bibr" rid="B22">22</xref>].</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients</title><p>Three hundred and eighty-two treatment na&#x000ef;ve HCV genotype 2 or 3 infected patients were included in a phase III, open label, randomized, multicenter, investigator-initiated trial (the NORDynamIC study) conducted at 31 centers in Denmark, Finland, Norway, and Sweden. Details regarding demographics and clinical characteristics have been previously reported [<xref ref-type="bibr" rid="B22">22</xref>]. Briefly, all patients were adults with compensated liver disease, had detectable HCV RNA, and were seronegative for hepatitis B surface antigen and for antibodies to human immune deficiency virus. A liver biopsy consistent with chronic hepatitis C within 24&#x02009;months prior to inclusion was also required. At study entry, patients were randomized to either 12 or 24&#x02009;weeks of treatment with 180&#x02009;&#x003bc;g of peg-interferon &#x003b1;-2a once weekly and 800&#x02009;mg/day ribavirin. After excluding all non-Caucasians as well as two patients positive for both HCV genotypes 2 and 3, a total of 359 patients were examined. Alcohol consumption was measured as standard drink units (12&#x02009;g of pure alcohol) per day [<xref ref-type="bibr" rid="B23">23</xref>].</p></sec><sec><title>PCR <italic>PNPLA3</italic> genotyping, rs738409</title><p>The variation at <italic>rs738409</italic> was determined by amplification on an ABI7300 (Applied Biosystems) using <italic>rs738409_F</italic>, GTGCCTGTCGTGTACTGAACCA as forward primer, <italic>rs738409_R</italic>, AGCGCGGAGTGCAATTCA as reverse primer, and Taqman MGB (minor groove binding) probes (<italic>rs738409-pC</italic>, FAM-CTGCTTCATCCCCTTC-MGB, <italic>rs738409-pG</italic>, VIC-GGAAGGAGGGATAAGGCCACT-MGB) for allelic discrimination.</p><sec><title>Serum metabolic parameters</title><p>Baseline fasting glucose (mmol/L) was measured at individual sites on freshly drawn serum, whereas fasting serum insulin was analyzed on frozen samples at the central laboratory (mU/L, Architect Insulin, Abbott, Abbott Park, IL). Diabetes mellitus was defined as fasting serum glucose&#x02009;&#x02265;&#x02009;7.0&#x02009;mmol/L. Insulin resistance was assessed by using the homeostatic model assessment insulin for resistance (HOMA-IR) index. The gold standard for insulin resistance assessment is the euglycemic hyperinsulinemic clamp technique [<xref ref-type="bibr" rid="B24">24</xref>]. However, this method is demanding and time-consuming and therefore is not commonly used in genetic and epidemiologic studies. The HOMA-IR is a well known and widely used surrogate index to quantify insulin resistance that is highly correlated with clamp estimations [<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B26">26</xref>]. HOMA-IR was calculated using the formula: (Glucose mmol/L&#x02009;&#x000d7;&#x02009;Insulin mU/L)/22.5 [<xref ref-type="bibr" rid="B27">27</xref>].</p></sec></sec><sec><title>Histological assessment</title><p>Fibrosis and necroinflammatory activity were assessed according to the Ishak protocol by two experienced observers in a dual observer consensus fashion as described [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. Specifically, presence of fibrosis was defined as Ishak stage &#x02265;1, and cirrhosis as Ishak stage 5&#x02013;6. Steatosis was graded as follows: absent (grade 0), mild (less than 30&#x02009;% of hepatocytes involved, grade 1), moderate (30-70&#x02009;% of hepatocytes involved, grade 2) or severe (&#x0003e;70&#x02009;% of hepatocytes involved, grade 3), although in the present study reported as absent or present (grade 1&#x02013;3).</p></sec><sec><title>HCV RNA quantification</title><p>HCV RNA was determined by RT-PCR of plasma using Cobas AmpliPrep/COBAS TaqMan HCV Test (Roche Diagnostics, Branchburg, NJ), which quantifies HCV RNA with a limit of detection of 15&#x02009;IU/mL. HCV RNA quantification was performed on days 0, 3, 7, 8, 29, and on weeks 8, 12, and 24 (for those receiving 24&#x02009;weeks of therapy), and 24&#x02009;weeks after completion of therapy. All samples were frozen (&#x02212;70&#x02009;&#x000b0;C), and subsequently analyzed at a central laboratory.</p></sec><sec><title>Statistical methods</title><p>Continuous variables were presented as median and the range between the 25th and 75th percentile (interquartile range). Categorical variable distributions were compared using either the <italic>&#x003c7;</italic><sup>2</sup> test or the Fisher&#x02019;s exact test. Continuous variables were analyzed with linear regression, when necessary after logarithmic transformation in order to create a normal distribution. Metabolic parameters were adjusted for age, gender and body mass index (BMI). Both additive (<italic>add</italic>) and recessive (<italic>rec</italic>) inheritance models were tested. Binary logistic regression analysis was used to calculate allelic odds ratio and 95&#x02009;% confidence interval. Frequency distribution of genetic variants was evaluated according to the Hardy Weinberg equilibrium. All statistical analyses were performed using the IBM SPSS statistics version 19 (IBM Corporation, Somers, NY) software package. A two-sided P-value of &#x0003c;0.05 was considered statistically significant.</p></sec><sec><title>Ethical considerations</title><p>The Regional Ethics Review Board in Gothenburg approved the study. All patients signed informed consent. The study is registered at the NIH trial registry (ClinicalTrials.gov Identifier: NCT00143000).</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title><italic>PNPLA3</italic> I148M genotype</title><p>A total of 359 individuals were analyzed for the <italic>PNPLA3</italic> I148M genotype (II, IM or MM). Among these, 103 were infected with HCV genotype 2 and 256 with genotype 3. The distribution of the <italic>PNPLA3</italic> I148M genotype was in Hardy Weinberg equilibrium (P&#x02009;=&#x02009;0.691 for genotype 2 and P&#x02009;=&#x02009;0.468 for genotype 3, Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>: Table S1). The <italic>PNPLA3</italic> I148M genotype frequency in our study cohort ( Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>: Table S1) was consistent with previously reported frequencies for Northern Europeans [<xref ref-type="bibr" rid="B29">29</xref>]. Study group characteristics stratified by HCV genotype 2 or HCV genotype 3 infection are described in Table <xref ref-type="table" rid="T1">1</xref>. Individuals with HCV genotype 2 infection were on average nine years older, they had lower alanine transferase (ALT) levels and lower degree of steatosis compared to individuals with HCV genotype 3 infection. They also had higher total cholesterol and HCV RNA at baseline compared to the HCV genotype 3 group (Table <xref ref-type="table" rid="T1">1</xref>). </p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Baseline characteristics stratified by HCV genotype</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left">&#x000a0;</th><th align="center"><bold>HCV genotype 2 n&#x02009;=&#x02009;103</bold></th><th align="center"><bold>HCV genotype 3 n&#x02009;=&#x02009;256</bold></th><th align="center"><bold>P value</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold>Male gender, n (%)</bold><hr/></td><td align="char" valign="bottom" char="(">62 (60)<hr/></td><td align="char" valign="bottom" char="(">154 (60)<hr/></td><td align="char" valign="bottom" char=".">0.920<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Age, years</bold><hr/></td><td align="char" valign="bottom" char="(">49 (41&#x02013;54)<hr/></td><td align="char" valign="bottom" char="(">40 (32&#x02013;48)<hr/></td><td align="char" valign="bottom" char=".">&#x0003c;0.001<hr/></td></tr><tr><td align="left" valign="bottom"><bold>BMI, kg/m</bold><sup>
<bold>2</bold>
</sup><hr/></td><td align="char" valign="bottom" char="(">25<sup>a</sup> (23&#x02013;27)<hr/></td><td align="char" valign="bottom" char="(">25<sup>b</sup> (23&#x02013;28)<hr/></td><td align="char" valign="bottom" char=".">0.290<hr/></td></tr><tr><td align="left" valign="bottom"><bold>ALT, U/l</bold><hr/></td><td align="char" valign="bottom" char="(">74<sup>a</sup> (44&#x02013;144)<hr/></td><td align="char" valign="bottom" char="(">108<sup>a</sup> (66&#x02013;175)<hr/></td><td align="char" valign="bottom" char=".">&#x0003c;0.001<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Total cholesterol, mmol/L</bold><hr/></td><td align="char" valign="bottom" char="(">4.6<sup>c</sup> (4.1-5.4)<hr/></td><td align="char" valign="bottom" char="(">3.9<sup>d</sup> (3.3-4.6)<hr/></td><td align="char" valign="bottom" char=".">&#x0003c;0.001<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Triglycerides, mmol/L</bold><hr/></td><td align="char" valign="bottom" char="(">0.9<sup>c</sup> (0.7-1.3)<hr/></td><td align="char" valign="bottom" char="(">0.9<sup>d</sup> (0.7-1.4)<hr/></td><td align="char" valign="bottom" char=".">0.748<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Glucose, mmol/L</bold><hr/></td><td align="char" valign="bottom" char="(">4.9<sup>d</sup> (4.6-5.4)<hr/></td><td align="char" valign="bottom" char="(">4.9<sup>e</sup> (4.5-5.4)<hr/></td><td align="char" valign="bottom" char=".">0.507<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Insulin, mIU/L</bold><hr/></td><td align="char" valign="bottom" char="(">12<sup>f</sup> (6&#x02013;24)<hr/></td><td align="char" valign="bottom" char="(">12<sup>e</sup> (7&#x02013;26)<hr/></td><td align="char" valign="bottom" char=".">0.458<hr/></td></tr><tr><td align="left" valign="bottom"><bold>HOMA-IR, U</bold><hr/></td><td align="char" valign="bottom" char="(">2.5<sup>g</sup> (1.3-6.0)<hr/></td><td align="char" valign="bottom" char="(">2.7<sup>h</sup> (1.6-5.9)<hr/></td><td align="char" valign="bottom" char=".">0.088<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Baseline HCV RNA, log</bold><sub>
<bold>10</bold>
</sub><bold>IU/mL</bold><hr/></td><td align="char" valign="bottom" char="(">6.5 (5.8-6.8)<hr/></td><td align="char" valign="bottom" char="(">6.1 (5.4-6.7)<hr/></td><td align="char" valign="bottom" char=".">0.025<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Steatosis</bold><sup>
<bold>1</bold>
</sup><bold>, n (%)</bold><hr/></td><td align="char" valign="bottom" char="(">49<sup>c</sup> (50)<hr/></td><td align="char" valign="bottom" char="(">171<sup>i</sup> (73)<hr/></td><td align="char" valign="bottom" char=".">&#x0003c;0.001<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Cirrhosis</bold><sup>
<bold>2</bold>
</sup><bold>, n (%)</bold><hr/></td><td align="char" valign="bottom" char="(">14<sup>c</sup> (14)<hr/></td><td align="char" valign="bottom" char="(">29<sup>i</sup> (12)<hr/></td><td align="char" valign="bottom" char=".">0.807<hr/></td></tr><tr><td align="left"><bold>Diabetes mellitus, n (%)</bold></td><td align="char" char="(">4<sup>d</sup> (4)</td><td align="char" char="(">7<sup>e</sup> (3)</td><td align="char" char=".">0.823</td></tr></tbody></table><table-wrap-foot><p>Categorical traits, expressed as number (n) and relative proportion (%), have been compared by <italic>&#x003c7;</italic><sup>2</sup> test. Continuous traits are expressed as median (interquartile range) and have been analyzed using a linear regression model. For additional information on statistical analyses, see methods.</p><p><sup>1</sup>Steatosis was defined as histological grade&#x02009;&#x0003e;&#x02009;0. <sup>2</sup>Cirrhosis was defined as Ishak stage 5&#x02013;6.</p><p>Missing data: <sup>a</sup>n&#x02009;=&#x02009;1, <sup>b</sup>n&#x02009;=&#x02009;8, <sup>c</sup>n&#x02009;=&#x02009;4, <sup>d</sup>n&#x02009;=&#x02009;6, <sup>e</sup>n&#x02009;=&#x02009;15, <sup>f</sup>n&#x02009;=&#x02009;7, <sup>g</sup>n&#x02009;=&#x02009;13, <sup>h</sup>n&#x02009;=&#x02009;27,<sup>i</sup>n&#x02009;=&#x02009;23.</p><p><italic>Abbreviations:</italic> HCV, hepatitis C virus; BMI, body mass index; ALT, alanine transferase; HOMA-IR, homeostasis model assessment for insulin resistance; II, individuals with two 148I alleles; MM, individuals with two 148&#x02009;M alleles; IM, heterozygotes.</p></table-wrap-foot></table-wrap></sec><sec><title>Clinical and biochemical profile</title><p><italic>PNPLA3</italic> 148M allele carriers were found to have increased insulin resistance in HCV genotype 2 infected patients (P<italic>add</italic>&#x02009;=&#x02009;0.023, P<italic>rec</italic>&#x02009;=&#x02009;0.005; Table <xref ref-type="table" rid="T2">2</xref> and Figure <xref ref-type="fig" rid="F1">1</xref> A). No association with insulin resistance and the <italic>PNPLA3</italic> 148M allele was found in individuals with HCV genotype 3 (Table <xref ref-type="table" rid="T3">3</xref> and Figure <xref ref-type="fig" rid="F1">1</xref> B). Results were virtually identical after excluding individuals with diabetes mellitus (HCV genotype 2 HOMA-IR (U): II 1.8 [1.1-4.2], IM 3.0 [1.4-6.7], MM 9.0 [4.8-21.7]; P<italic>add</italic>&#x02009;=&#x02009;0.003, P<italic>rec</italic>&#x02009;=&#x02009;0.002; HCV genotype 3 HOMA-IR (U): II 2.6 [1.5-5.8], IM 2.6 [1.6-4.8], MM 2.5 [1.5-8.4]; P<italic>add</italic>&#x02009;=&#x02009;0.811, P<italic>rec</italic>&#x02009;=&#x02009;0.973). No significant association of triglyceride levels with <italic>PNPLA3</italic> I148M genotypes was found in either HCV genotype 2 or 3 patients (Tables <xref ref-type="table" rid="T2">2</xref> and <xref ref-type="table" rid="T3">3</xref>). In HCV genotype 2 individuals, the <italic>PNPLA3</italic> 148M allele was found to be associated with higher ALT levels only if analyzed under a recessive inheritance model (P<italic>rec</italic>&#x02009;=&#x02009;0.045, Table <xref ref-type="table" rid="T2">2</xref>). Carriage of the <italic>PNPLA3</italic> 148M allele was not associated with age, gender, BMI or total cholesterol in either HCV genotype group (Tables <xref ref-type="table" rid="T2">2</xref> and <xref ref-type="table" rid="T3">3</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p><bold>Baseline characteristics according to</bold><bold>
<italic>PNPLA3</italic>
</bold><bold>I148M sequence variant in HCV genotype 2 patients</bold></p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th rowspan="2" align="left">&#x000a0;</th><th align="center" valign="bottom"><bold>II</bold><hr/></th><th align="center" valign="bottom"><bold>IM</bold><hr/></th><th align="center" valign="bottom"><bold>MM</bold><hr/></th><th align="center" valign="bottom"><bold>P value</bold><hr/></th><th align="center" valign="bottom"><bold>P value</bold><hr/></th></tr><tr><th align="center"><bold>n&#x02009;=&#x02009;56</bold></th><th align="center"><bold>n&#x02009;=&#x02009;43</bold></th><th align="center"><bold>n&#x02009;=&#x02009;4</bold></th><th align="center"><bold>
<italic>additive</italic>
</bold></th><th align="center"><bold>
<italic>recessive</italic>
</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold>Male gender, n (%)</bold><hr/></td><td align="char" valign="bottom" char="(">33 (59)<hr/></td><td align="char" valign="bottom" char="(">27 (63)<hr/></td><td align="char" valign="bottom" char="(">2 (50)<hr/></td><td align="char" valign="bottom" char=".">0.830<hr/></td><td align="char" valign="bottom" char=".">0.999<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Age, years</bold><hr/></td><td align="char" valign="bottom" char="(">50 (42&#x02013;56)<hr/></td><td align="char" valign="bottom" char="(">48 (37&#x02013;54)<hr/></td><td align="char" valign="bottom" char="(">51 (36&#x02013;53)<hr/></td><td align="char" valign="bottom" char=".">0.370<hr/></td><td align="char" valign="bottom" char=".">0.887<hr/></td></tr><tr><td align="left" valign="bottom"><bold>BMI, kg/m</bold><sup>
<bold>2</bold>
</sup><hr/></td><td align="char" valign="bottom" char="(">25 (23&#x02013;27)<hr/></td><td align="char" valign="bottom" char="(">25<sup>a</sup> (22&#x02013;27)<hr/></td><td align="char" valign="bottom" char="(">23 (21&#x02013;33)<hr/></td><td align="char" valign="bottom" char=".">0.773<hr/></td><td align="char" valign="bottom" char=".">0.981<hr/></td></tr><tr><td align="left" valign="bottom"><bold>ALT, U/l</bold><hr/></td><td align="char" valign="bottom" char="(">73<sup>a</sup> (44&#x02013;150)<hr/></td><td align="char" valign="bottom" char="(">72 (39&#x02013;137)<hr/></td><td align="char" valign="bottom" char="(">147 (88&#x02013;455)<hr/></td><td align="char" valign="bottom" char=".">0.406<hr/></td><td align="char" valign="bottom" char=".">0.045<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Total cholesterol, mmol/L</bold><hr/></td><td align="char" valign="bottom" char="(">4.8<sup>b</sup> (4.1-5.5)<hr/></td><td align="char" valign="bottom" char="(">4.6<sup>a</sup> (4.2-5.1)<hr/></td><td align="char" valign="bottom" char="(">4.2 (3.9-5.8)<hr/></td><td align="char" valign="bottom" char=".">0.283<hr/></td><td align="char" valign="bottom" char=".">0.756<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Triglycerides, mmol/L</bold><hr/></td><td align="char" valign="bottom" char="(">1.0<sup>b</sup> (0.8-1.3)<hr/></td><td align="char" valign="bottom" char="(">0.9<sup>a</sup> (0.7-1.3)<hr/></td><td align="char" valign="bottom" char="(">0.7 (0.4-1.3)<hr/></td><td align="char" valign="bottom" char=".">0.094<hr/></td><td align="char" valign="bottom" char=".">0.065<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Glucose, mmol/L</bold><hr/></td><td align="char" valign="bottom" char="(">4.9<sup>d</sup> (4.6-5.1)<hr/></td><td align="char" valign="bottom" char="(">5.0<sup>e</sup> (4.5-5.4)<hr/></td><td align="char" valign="bottom" char="(">4.5 (4.2-5.6)<hr/></td><td align="char" valign="bottom" char=".">0.502<hr/></td><td align="char" valign="bottom" char=".">0.724<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Insulin, mIU/L</bold><hr/></td><td align="char" valign="bottom" char="(">10<sup>d</sup> (5&#x02013;23)<hr/></td><td align="char" valign="bottom" char="(">13<sup>c</sup> (7&#x02013;29)<hr/></td><td align="char" valign="bottom" char="(">48 (24&#x02013;86)<hr/></td><td align="char" valign="bottom" char=".">0.027<hr/></td><td align="char" valign="bottom" char=".">0.001<hr/></td></tr><tr><td align="left" valign="bottom"><bold>HOMA-IR, U</bold><hr/></td><td align="char" valign="bottom" char="(">1.9<sup>e</sup> (1.1-4.5)<hr/></td><td align="char" valign="bottom" char="(">2.9<sup>f</sup> (1.4-6.7)<hr/></td><td align="char" valign="bottom" char="(">9.0 (4.8-21.7)<hr/></td><td align="char" valign="bottom" char=".">0.023<hr/></td><td align="char" valign="bottom" char=".">0.005<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Baseline HCV RNA, log</bold><sub>
<bold>10</bold>
</sub><bold>IU/mL</bold><hr/></td><td align="char" valign="bottom" char="(">6.5 (6.0-6.9)<hr/></td><td align="char" valign="bottom" char="(">6.4 (5.3-6.8)<hr/></td><td align="char" valign="bottom" char="(">5.3 (4.7-6.4)<hr/></td><td align="char" valign="bottom" char=".">0.005<hr/></td><td align="char" valign="bottom" char=".">0.073<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Steatosis</bold><sup>
<bold>1</bold>
</sup><bold>, n (%)</bold><hr/></td><td align="char" valign="bottom" char="(">23<sup>b</sup> (43)<hr/></td><td align="char" valign="bottom" char="(">23<sup>a</sup> (55)<hr/></td><td align="char" valign="bottom" char="(">3 (75)<hr/></td><td align="char" valign="bottom" char=".">0.327<hr/></td><td align="char" valign="bottom" char=".">0.362<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Cirrhosis</bold><sup>
<bold>2</bold>
</sup><bold>, n (%)</bold><hr/></td><td align="char" valign="bottom" char="(">7<sup>b</sup> (13)<hr/></td><td align="char" valign="bottom" char="(">6<sup>a</sup> (14)<hr/></td><td align="char" valign="bottom" char="(">1 (25)<hr/></td><td align="char" valign="bottom" char=".">0.669<hr/></td><td align="char" valign="bottom" char=".">0.462<hr/></td></tr><tr><td align="left"><bold>Diabetes mellitus, n (%)</bold></td><td align="char" char="(">3<sup>d</sup> (6)</td><td align="char" char="(">1<sup>e</sup> (3)</td><td align="char" char="(">0 (0)</td><td align="char" char=".">0.694</td><td align="char" char=".">0.998</td></tr></tbody></table><table-wrap-foot><p>Categorical traits, expressed as number (n) and relative proportion (%), have been compared by Fisher exact test. Continuous traits are expressed as median (interquartile range) and have been analyzed using a linear regression model. For additional information on statistical analyses, see methods.</p><p><sup>1</sup>Steatosis was defined as histological grade&#x02009;&#x0003e;&#x02009;0. <sup>2</sup>Cirrhosis was defined as Ishak stage 5&#x02013;6.</p><p>Missing data: <sup>a</sup>n&#x02009;=&#x02009;1, <sup>b</sup>n&#x02009;=&#x02009;3, <sup>c</sup>n&#x02009;=&#x02009;5, <sup>d</sup>n&#x02009;=&#x02009;2, <sup>e</sup>n&#x02009;=&#x02009;4, <sup>f</sup>n&#x02009;=&#x02009;9.</p><p><italic>Abbreviations:</italic> PNPLA3, patatin-like phospholipase domain-containing 3; HCV, hepatitis C virus; BMI, body mass index; ALT, alanine transferase; HOMA-IR, homeostasis model assessment for insulin resistance; II, individuals with two 148I alleles; MM, individuals with two 148&#x02009;M alleles; IM, heterozygotes.</p></table-wrap-foot></table-wrap><fig id="F1" position="float"><label>Figure 1 </label><caption><p><bold>Homeostasis model assessment for insulin resistance (HOMA-IR) in HCV genotype 2 (A) and genotype 3 (B) infected patients, stratified by the </bold><bold><italic>PNPLA3 </italic></bold><bold>I148M genotype.</bold> P values were calculated using linear regression after logarithmic transformation of HOMA-IR values and adjusted for age, gender and BMI.</p></caption><graphic xlink:href="1471-2350-13-82-1"/></fig><table-wrap position="float" id="T3"><label>Table 3</label><caption><p><bold>Baseline characteristics according to</bold><bold>
<italic>PNPLA3</italic>
</bold><bold>I148M sequence variant in HCV genotype 3 patients</bold></p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th rowspan="2" align="left">&#x000a0;</th><th align="center" valign="bottom"><bold>II</bold><hr/></th><th align="center" valign="bottom"><bold>IM</bold><hr/></th><th align="center" valign="bottom"><bold>MM</bold><hr/></th><th align="center" valign="bottom"><bold>P value</bold><hr/></th><th align="center" valign="bottom"><bold>P value</bold><hr/></th></tr><tr><th align="center"><bold>n&#x02009;=&#x02009;159</bold></th><th align="center"><bold>n&#x02009;=&#x02009;91</bold></th><th align="center"><bold>n&#x02009;=&#x02009;6</bold></th><th align="center"><bold>
<italic>additive</italic>
</bold></th><th align="center"><bold>
<italic>recessive</italic>
</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold>Male gender, n (%)</bold><hr/></td><td align="char" valign="bottom" char="(">97 (61)<hr/></td><td align="char" valign="bottom" char="(">52 (57)<hr/></td><td align="char" valign="bottom" char="(">5 (83)<hr/></td><td align="char" valign="bottom" char=".">0.466<hr/></td><td align="char" valign="bottom" char=".">0.407<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Age, years</bold><hr/></td><td align="char" valign="bottom" char="(">39 (31&#x02013;47)<hr/></td><td align="char" valign="bottom" char="(">41 (35&#x02013;48)<hr/></td><td align="char" valign="bottom" char="(">42 (29&#x02013;46)<hr/></td><td align="char" valign="bottom" char=".">0.128<hr/></td><td align="char" valign="bottom" char=".">0.653<hr/></td></tr><tr><td align="left" valign="bottom"><bold>BMI, kg/m</bold><sup>
<bold>2</bold>
</sup><hr/></td><td align="char" valign="bottom" char="(">26<sup>a</sup> (23&#x02013;29)<hr/></td><td align="char" valign="bottom" char="(">25<sup>a</sup> (23&#x02013;28)<hr/></td><td align="char" valign="bottom" char="(">26 (22&#x02013;28)<hr/></td><td align="char" valign="bottom" char=".">0.232<hr/></td><td align="char" valign="bottom" char=".">0.644<hr/></td></tr><tr><td align="left" valign="bottom"><bold>ALT, U/l</bold><hr/></td><td align="char" valign="bottom" char="(">108 (68&#x02013;175)<hr/></td><td align="char" valign="bottom" char="(">106<sup>d</sup> (62&#x02013;181)<hr/></td><td align="char" valign="bottom" char="(">69 (61&#x02013;109)<hr/></td><td align="char" valign="bottom" char=".">0.398<hr/></td><td align="char" valign="bottom" char=".">0.248<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Total cholesterol, mmol/L</bold><hr/></td><td align="char" valign="bottom" char="(">4.0<sup>e</sup> (3.3-4.7)<hr/></td><td align="char" valign="bottom" char="(">3.8<sup>a</sup> (3.2-4.5)<hr/></td><td align="char" valign="bottom" char="(">3.7 (3.1-5.7)<hr/></td><td align="char" valign="bottom" char=".">0.909<hr/></td><td align="char" valign="bottom" char=".">0.452<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Triglycerides, mmol/L</bold><hr/></td><td align="char" valign="bottom" char="(">0.9<sup>e</sup> (0.7-1.3)<hr/></td><td align="char" valign="bottom" char="(">0.9<sup>a</sup> (0.7-1.4)<hr/></td><td align="char" valign="bottom" char="(">0.8 (0.6-1.1)<hr/></td><td align="char" valign="bottom" char=".">0.336<hr/></td><td align="char" valign="bottom" char=".">0.256<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Glucose, mmol/L</bold><hr/></td><td align="char" valign="bottom" char="(">4.9<sup>c</sup> (4.5-5.6)<hr/></td><td align="char" valign="bottom" char="(">4.9<sup>f</sup> (4.6-5.3)<hr/></td><td align="char" valign="bottom" char="(">4.8 (4.6-5.4)<hr/></td><td align="char" valign="bottom" char=".">0.147<hr/></td><td align="char" valign="bottom" char=".">0.882<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Insulin, mIU/L</bold><hr/></td><td align="char" valign="bottom" char="(">13<sup>g</sup> (7&#x02013;26)<hr/></td><td align="char" valign="bottom" char="(">12<sup>h</sup> (7&#x02013;25)<hr/></td><td align="char" valign="bottom" char="(">12 (6&#x02013;39)<hr/></td><td align="char" valign="bottom" char=".">0.800<hr/></td><td align="char" valign="bottom" char=".">0.785<hr/></td></tr><tr><td align="left" valign="bottom"><bold>HOMA-IR, U</bold><hr/></td><td align="char" valign="bottom" char="(">2.7<sup>i</sup> (1.5-6.1)<hr/></td><td align="char" valign="bottom" char="(">2.6<sup>j</sup> (1.6-4.7)<hr/></td><td align="char" valign="bottom" char="(">2.5 (1.5-8.4)<hr/></td><td align="char" valign="bottom" char=".">0.882<hr/></td><td align="char" valign="bottom" char=".">0.941<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Baseline HCV RNA, log</bold><sub>
<bold>10</bold>
</sub><bold>IU/mL</bold><hr/></td><td align="char" valign="bottom" char="(">6.0 (5.3-6.7)<hr/></td><td align="char" valign="bottom" char="(">6.2 (5.6-6.7)<hr/></td><td align="char" valign="bottom" char="(">6.8 (6.1-7.1)<hr/></td><td align="char" valign="bottom" char=".">0.030<hr/></td><td align="char" valign="bottom" char=".">0.100<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Steatosis</bold><sup>
<bold>1</bold>
</sup><bold>, n (%)</bold><hr/></td><td align="char" valign="bottom" char="(">99<sup>k</sup> (68)<hr/></td><td align="char" valign="bottom" char="(">68<sup>c</sup> (82)<hr/></td><td align="char" valign="bottom" char="(">4<sup>d</sup> (80)<hr/></td><td align="char" valign="bottom" char=".">0.068<hr/></td><td align="char" valign="bottom" char=".">0.989<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Cirrhosis</bold><sup>
<bold>3</bold>
</sup><bold>, n (%)</bold><hr/></td><td align="char" valign="bottom" char="(">17<sup>k</sup> (12)<hr/></td><td align="char" valign="bottom" char="(">11<sup>c</sup> (13)<hr/></td><td align="char" valign="bottom" char="(">1<sup>d</sup> (20)<hr/></td><td align="char" valign="bottom" char=".">0.636<hr/></td><td align="char" valign="bottom" char=".">0.489<hr/></td></tr><tr><td align="left"><bold>Diabetes mellitus, n (%)</bold></td><td align="char" char="(">6<sup>c</sup> (4)</td><td align="char" char="(">1<sup>f</sup> (1)</td><td align="char" char="(">0 (0)</td><td align="char" char=".">0.520</td><td align="char" char=".">0.996</td></tr></tbody></table><table-wrap-foot><p>Categorical traits, expressed as number (n) and relative proportion (%), have been compared by Fisher exact test. Continuous traits are expressed as median (interquartile range) and have been analyzed using a linear regression model. For additional information on statistical analyses, see methods.</p><p><sup>1</sup>Steatosis was defined as histological grade&#x02009;&#x0003e;&#x02009;0. <sup>2</sup>Cirrhosis was defined as Ishak stage 5&#x02013;6.</p><p>Missing data: <sup>a</sup>n&#x02009;=&#x02009;4, <sup>b</sup>n&#x02009;=&#x02009;18, <sup>c</sup>n&#x02009;=&#x02009;8, <sup>d</sup>n&#x02009;=&#x02009;1, <sup>e</sup>n&#x02009;=&#x02009;2, <sup>f</sup>n&#x02009;=&#x02009;7, <sup>g</sup>n&#x02009;=&#x02009;9, <sup>h</sup>n&#x02009;=&#x02009;6, <sup>i</sup>n&#x02009;=&#x02009;16, <sup>j</sup>n&#x02009;=&#x02009;11, <sup>k</sup>n&#x02009;=&#x02009;14. <italic>Abbreviations:</italic> PNPLA3, patatin-like phospholipase domain-containing 3; HCV, hepatitis C virus; BMI, body mass index; ALT, alanine transferase; HOMA-IR, homeostasis model assessment for insulin resistance; II, individuals with two 148I alleles; MM, individuals with two 148&#x02009;M alleles; IM, heterozygotes.</p></table-wrap-foot></table-wrap></sec><sec><title>Viral kinetics</title><p>Among the HCV genotype 2 infected individuals, the <italic>PNPLA3</italic> 148M allele was associated with lower viral load at baseline (P<italic>add</italic>&#x02009;=&#x02009;0.005, P<italic>rec</italic>&#x02009;=&#x02009;0.073, Table <xref ref-type="table" rid="T2">2</xref>), on day 3 (P<italic>add</italic>&#x02009;=&#x02009;0.014 P<italic>rec</italic>&#x02009;=&#x02009;0.130) and on day 7 (P<italic>add</italic>&#x02009;=&#x02009;0.003, P<italic>rec</italic>&#x02009;=&#x02009;0.036; Figure <xref ref-type="fig" rid="F2">2</xref>A). In contrast, HCV genotype 3 patients with the <italic>PNPLA3</italic> 148M allele genotype had higher baseline viral load (P<italic>add</italic>&#x02009;=&#x02009;0.030, P<italic>rec</italic>&#x02009;=&#x02009;0.100, Table <xref ref-type="table" rid="T3">3</xref>). No further associations between the <italic>PNPLA3</italic> genotype and viral load during treatment (Figure <xref ref-type="fig" rid="F2">2</xref>B), first or second phase decline in HCV RNA, or final treatment outcome (sustained viral response rate in the HCV genotype 2 group was 66, 70 and 100&#x02009;% and in the HCV genotype 3 group 67, 74 and 67&#x02009;%, respectively in the II, IM and MM groups respectively), were observed.</p><fig id="F2" position="float"><label>Figure 2 </label><caption><p><bold>HCV viral load according to the </bold><bold><italic>PNPLA3 </italic></bold><bold>I148M genotype in HCV genotype 2 (A) and genotype 3 (B) infected patients from start of treatment (day 0) through treatment week 12 (day 84).</bold> Viral load is expressed as mean log<sub>10</sub> value at each time point. P values were calculated for the difference in viral load across <italic>PNPLA3</italic> I148M genotypes at each time point using linear regression.</p></caption><graphic xlink:href="1471-2350-13-82-2"/></fig></sec><sec><title>Liver histology</title><p>A trend, although non-significant, towards a higher prevalence of steatosis was observed in <italic>PNPLA3</italic> 148M allele carriers in both HCV genotype 2 and 3 subjects (Tables <xref ref-type="table" rid="T2">2</xref> and <xref ref-type="table" rid="T3">3</xref>). <italic>PNPLA3</italic> 148M allele was found associated with hepatic steatosis increased risk, although non-significant, in HCV genotype 2 (allelic Odds Ratio, O.R.&#x02009;=&#x02009;2.3, 95&#x02009;% Confidence Interval C.I.&#x02009;=&#x02009;0.9-5.5, P<italic>add</italic>&#x02009;=&#x02009;0.053, P<italic>rec</italic>&#x02009;=&#x02009;0.154, after adjustment for age, gender and BMI) and 3 (allelic O.R.&#x02009;=&#x02009;1.7, 95&#x02009;%&#x02009;C.I.&#x02009;=&#x02009;0.9-3.4, P<italic>add</italic>&#x02009;=&#x02009;0.096, P<italic>rec</italic>&#x02009;=&#x02009;0.991, after adjustment for age, gender and BMI) subjects. No association between the prevalence of cirrhosis and the <italic>PNPLA3</italic> 148M allele was observed in either HCV genotype 2 or 3 infected subjects (Tables <xref ref-type="table" rid="T2">2</xref> and <xref ref-type="table" rid="T3">3</xref>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The main finding of the present study is the association between the <italic>PNPLA3</italic> 148M allele and increased insulin resistance and lower baseline viral load among HCV genotype 2 infected patients. <italic>PNPLA3</italic> I148M is the most widely replicated genetic variant associated with increased hepatic steatosis [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. Moreover, <italic>PNPLA3</italic> 148M allele carriers with HCV infection have been reported to have increased prevalence of steatosis, fibrosis, cirrhosis and hepatocellular carcinoma [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B21">21</xref>]. Recent studies on the <italic>PNPLA3</italic> 148M allele and glucose metabolism suggest a possible involvement of this allele as a genetic determinant [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>].</p><p>In this study an association between increased insulin resistance and the <italic>PNPLA3</italic> 148M allele was observed. This association was specifically present in HCV genotype 2 and it was not observed among HCV genotype 3 infected patients. Steatosis is tightly associated with insulin resistance [<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>]; however, the causal nature of this association remains to be fully elucidated. Insulin resistance has been commonly thought to be a risk factor for liver fat accumulation [<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B34">34</xref>]. Nevertheless, new evidence suggests that hepatic steatosis might be pathogenically responsible for the development of insulin resistance [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B35">35</xref>]. The association of <italic>PNPLA3</italic> 148M allele with HOMA-IR in HCV infected subjects supports the hypothesis that insulin resistance may be interpreted as a consequence rather than a cause of hepatic steatosis. To date the role of the <italic>PNPLA3</italic> I148M variant on insulin resistance has been controversial, having some previous studies failed to find this association [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B15">15</xref>]; however our result is consistent with a recent study performed in normoglycaemic subjects from Taiwan [<xref ref-type="bibr" rid="B16">16</xref>] that reports 148M allele carriers having higher HOMA-IR levels. Further studies in larger cohorts are warranted to confirm this result.</p><p>Interestingly, we found that lower baseline viral load was associated with the <italic>PNPLA3</italic> 148M allele in HCV genotype 2 but not in HCV genotype 3 infected patients. This finding is novel [<xref ref-type="bibr" rid="B20">20</xref>], although difficult to interpret. HCV has been shown to exploit lipoprotein assembly and export pathways for the release of virions from infected hepatocytes [<xref ref-type="bibr" rid="B36">36</xref>-<xref ref-type="bibr" rid="B38">38</xref>]. Since <italic>PNPLA3</italic> 148M allele has been reported to influence lipid accumulation in the liver [<xref ref-type="bibr" rid="B39">39</xref>]<italic>,</italic> it is possible to hypothesize that <italic>PNPLA3</italic> 148M allele may impair both viral and lipoprotein release from infected hepatocytes resulting in lower baseline plasma viral load in HCV genotype 2 infection. In the presence of HCV genotype 3 infection, however, the intrahepatic impact of <italic>PNPLA3</italic> 148M allele on lipid particle production appears to be overridden by viral factors.</p><p>An important limitation of the present study is the relative small sample size of the HCV genotype 2 infected patients, as well as relative lower rate of <italic>PNPLA3</italic> 148M allele carriage in Northern Europeans as compared to previous reports from Southern Europe. In fact, even though steatosis has been widely reported to be associated with <italic>PNPLA3</italic> 148M allele [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B20">20</xref>], only a non-significant trend towards higher prevalence of steatosis was observed among <italic>PNPLA3</italic> 148M allele carriers in both HCV genotypes in the present study. However, in the analysis adjusted for confounders, the increased risk of steatosis reached marginal significance in genotype 2 but not 3 infected individuals, despite the threefold larger sample size of the latter group. This is in line with previous data showing an association between the <italic>PNPLA3</italic> I148M genotype and steatosis in the HCV genotype 2 but not in the HCV genotype 3 infected subjects [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. Similarly, the relative small sample size of HCV genotype 2 infected patients in the present study may have contributed to the lack of association of the <italic>PNPLA3</italic> 148M allele with therapeutic outcome despite its effect on baseline viral load and insulin resistance. It is important to bear in mind that given the small sample size our results should be carefully interpreted due to the possibility of both false positive and negative associations. Therefore, this should be considered as a preliminary report and the results need to be confirmed in larger patient cohorts.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Our results suggest an association between the <italic>PNPLA3</italic> 148M allele and insulin resistance as well as viral load in HCV genotype 2, but not genotype 3 infected individuals. Additional further genetic studies are required to elucidate the relationship between HCV infection, metabolic traits and <italic>PNPLA3</italic> I148M genetic variant.</p></sec><sec><title>Competing interests</title><p>None of the authors have an association that might pose a conflict of interest.</p></sec><sec><title>Authors&#x02019; contributions</title><p>KR, CM: equal contributions; responsible for data compilation, statistical modeling and writing of the manuscript. JW, SR: equal contributions; planning and performing of the study, data compilation, statistical modeling, corresponding authors, writing of the manuscript. MLa, CP, MAB, KH : planning and performing of the study, data compilation, statistical modeling, writing of the manuscript. MLi: responsible for genetic analyses. PBC, MF, NL, MRB, CP, KM, GN: clinical management of patients, planning and performing the treatment trial. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/13/82/prepub">http://www.biomedcentral.com/1471-2350/13/82/prepub</ext-link></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold> Table S1.</bold> Genotype and allele frequencies of the PNPLA3 I148M sequence variant in HCV genotype 2 and 3 individuals.</p></caption><media xlink:href="1471-2350-13-82-S1.docx"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><sec><title>Acknowledgements</title><p>The authors would like to thank Ann-Sofie Tyl&#x000f6; for expert technical assistance. This study was funded by The Swedish Research Counsil (grant no: 523-2011-3821) and ALF Funds at the Sahlgrenska University Hospital (grant no: ALFGBG-143271). Roche affiliates in the Nordic region supported this study.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Lauer</surname><given-names>GM</given-names></name><name><surname>Walker</surname><given-names>BD</given-names></name><article-title>Hepatitis C virus infection</article-title><source>N Engl J Med</source><year>2001</year><volume>345</volume><issue>1</issue><fpage>41</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1056/NEJM200107053450107</pub-id><pub-id pub-id-type="pmid">11439948</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Lonardo</surname><given-names>A</given-names></name><name><surname>Adinolfi</surname><given-names>LE</given-names></name><name><surname>Loria</surname><given-names>P</given-names></name><name><surname>Carulli</surname><given-names>N</given-names></name><name><surname>Ruggiero</surname><given-names>G</given-names></name><name><surname>Day</surname><given-names>CP</given-names></name><article-title>Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease</article-title><source>Gastroenterology</source><year>2004</year><volume>126</volume><issue>2</issue><fpage>586</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2003.11.020</pub-id><pub-id pub-id-type="pmid">14762795</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Westin</surname><given-names>J</given-names></name><name><surname>Lagging</surname><given-names>M</given-names></name><name><surname>Dhillon</surname><given-names>AP</given-names></name><name><surname>Norkrans</surname><given-names>G</given-names></name><name><surname>Romero</surname><given-names>AI</given-names></name><name><surname>Pawlotsky</surname><given-names>JM</given-names></name><name><surname>Zeuzem</surname><given-names>S</given-names></name><name><surname>Schalm</surname><given-names>SW</given-names></name><name><surname>Verheij-Hart</surname><given-names>E</given-names></name><name><surname>Negro</surname><given-names>F</given-names></name><etal/><article-title>Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection</article-title><source>J Viral Hepat</source><year>2007</year><volume>14</volume><issue>1</issue><fpage>29</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2893.2006.00777.x</pub-id><pub-id pub-id-type="pmid">17212641</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Adinolfi</surname><given-names>LE</given-names></name><name><surname>Gambardella</surname><given-names>M</given-names></name><name><surname>Andreana</surname><given-names>A</given-names></name><name><surname>Tripodi</surname><given-names>MF</given-names></name><name><surname>Utili</surname><given-names>R</given-names></name><name><surname>Ruggiero</surname><given-names>G</given-names></name><article-title>Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity</article-title><source>Hepatology</source><year>2001</year><volume>33</volume><issue>6</issue><fpage>1358</fpage><lpage>1364</lpage><pub-id pub-id-type="doi">10.1053/jhep.2001.24432</pub-id><pub-id pub-id-type="pmid">11391523</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Rubbia-Brandt</surname><given-names>L</given-names></name><name><surname>Fabris</surname><given-names>P</given-names></name><name><surname>Paganin</surname><given-names>S</given-names></name><name><surname>Leandro</surname><given-names>G</given-names></name><name><surname>Male</surname><given-names>PJ</given-names></name><name><surname>Giostra</surname><given-names>E</given-names></name><name><surname>Carlotto</surname><given-names>A</given-names></name><name><surname>Bozzola</surname><given-names>L</given-names></name><name><surname>Smedile</surname><given-names>A</given-names></name><name><surname>Negro</surname><given-names>F</given-names></name><article-title>Steatosis affects chronic hepatitis C progression in a genotype specific way</article-title><source>Gut</source><year>2004</year><volume>53</volume><issue>3</issue><fpage>406</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1136/gut.2003.018770</pub-id><pub-id pub-id-type="pmid">14960525</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Leandro</surname><given-names>G</given-names></name><name><surname>Mangia</surname><given-names>A</given-names></name><name><surname>Hui</surname><given-names>J</given-names></name><name><surname>Fabris</surname><given-names>P</given-names></name><name><surname>Rubbia-Brandt</surname><given-names>L</given-names></name><name><surname>Colloredo</surname><given-names>G</given-names></name><name><surname>Adinolfi</surname><given-names>LE</given-names></name><name><surname>Asselah</surname><given-names>T</given-names></name><name><surname>Jonsson</surname><given-names>JR</given-names></name><name><surname>Smedile</surname><given-names>A</given-names></name><etal/><article-title>Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data</article-title><source>Gastroenterology</source><year>2006</year><volume>130</volume><issue>6</issue><fpage>1636</fpage><lpage>1642</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2006.03.014</pub-id><pub-id pub-id-type="pmid">16697727</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Romeo</surname><given-names>S</given-names></name><name><surname>Kozlitina</surname><given-names>J</given-names></name><name><surname>Xing</surname><given-names>C</given-names></name><name><surname>Pertsemlidis</surname><given-names>A</given-names></name><name><surname>Cox</surname><given-names>D</given-names></name><name><surname>Pennacchio</surname><given-names>LA</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Cohen</surname><given-names>JC</given-names></name><name><surname>Hobbs</surname><given-names>HH</given-names></name><article-title>Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><issue>12</issue><fpage>1461</fpage><lpage>1465</lpage><pub-id pub-id-type="doi">10.1038/ng.257</pub-id><pub-id pub-id-type="pmid">18820647</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Kotronen</surname><given-names>A</given-names></name><name><surname>Johansson</surname><given-names>LE</given-names></name><name><surname>Johansson</surname><given-names>LM</given-names></name><name><surname>Roos</surname><given-names>C</given-names></name><name><surname>Westerbacka</surname><given-names>J</given-names></name><name><surname>Hamsten</surname><given-names>A</given-names></name><name><surname>Bergholm</surname><given-names>R</given-names></name><name><surname>Arkkila</surname><given-names>P</given-names></name><name><surname>Arola</surname><given-names>J</given-names></name><name><surname>Kiviluoto</surname><given-names>T</given-names></name><etal/><article-title>A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans</article-title><source>Diabetologia</source><year>2009</year><volume>52</volume><issue>6</issue><fpage>1056</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1007/s00125-009-1285-z</pub-id><pub-id pub-id-type="pmid">19224197</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Romeo</surname><given-names>S</given-names></name><name><surname>Sentinelli</surname><given-names>F</given-names></name><name><surname>Dash</surname><given-names>S</given-names></name><name><surname>Yeo</surname><given-names>GS</given-names></name><name><surname>Savage</surname><given-names>DB</given-names></name><name><surname>Leonetti</surname><given-names>F</given-names></name><name><surname>Capoccia</surname><given-names>D</given-names></name><name><surname>Incani</surname><given-names>M</given-names></name><name><surname>Maglio</surname><given-names>C</given-names></name><name><surname>Iacovino</surname><given-names>M</given-names></name><etal/><article-title>Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent</article-title><source>Int J Obes (Lond)</source><year>2010</year><volume>34</volume><issue>1</issue><fpage>190</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1038/ijo.2009.216</pub-id><pub-id pub-id-type="pmid">19844213</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Speliotes</surname><given-names>EK</given-names></name><name><surname>Butler</surname><given-names>JL</given-names></name><name><surname>Palmer</surname><given-names>CD</given-names></name><name><surname>Voight</surname><given-names>BF</given-names></name><name><surname>Hirschhorn</surname><given-names>JN</given-names></name><name><surname>Consortium</surname><given-names>G</given-names></name><name><surname>Consortium</surname><given-names>M</given-names></name><article-title>CRN N: PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease</article-title><source>Hepatology</source><year>2010</year><volume>52</volume><issue>3</issue><fpage>904</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1002/hep.23768</pub-id><pub-id pub-id-type="pmid">20648472</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Valenti</surname><given-names>L</given-names></name><name><surname>Alisi</surname><given-names>A</given-names></name><name><surname>Galmozzi</surname><given-names>E</given-names></name><name><surname>Bartuli</surname><given-names>A</given-names></name><name><surname>Del Menico</surname><given-names>B</given-names></name><name><surname>Alterio</surname><given-names>A</given-names></name><name><surname>Dongiovanni</surname><given-names>P</given-names></name><name><surname>Fargion</surname><given-names>S</given-names></name><name><surname>Nobili</surname><given-names>V</given-names></name><article-title>I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease</article-title><source>Hepatology</source><year>2010</year><volume>52</volume><issue>4</issue><fpage>1274</fpage><lpage>1280</lpage><pub-id pub-id-type="doi">10.1002/hep.23823</pub-id><pub-id pub-id-type="pmid">20648474</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Qiao</surname><given-names>A</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Ke</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Cui</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><etal/><article-title>Mouse patatin-like phospholipase domain-containing 3 influences systemic lipid and glucose homeostasis</article-title><source>Hepatology</source><year>2011</year><volume>54</volume><issue>2</issue><fpage>509</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1002/hep.24402</pub-id><pub-id pub-id-type="pmid">21547936</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Santoro</surname><given-names>N</given-names></name><name><surname>Kursawe</surname><given-names>R</given-names></name><name><surname>D'Adamo</surname><given-names>E</given-names></name><name><surname>Dykas</surname><given-names>DJ</given-names></name><name><surname>Zhang</surname><given-names>CK</given-names></name><name><surname>Bale</surname><given-names>AE</given-names></name><name><surname>Cal&#x000ed;</surname><given-names>AM</given-names></name><name><surname>Narayan</surname><given-names>D</given-names></name><name><surname>Shaw</surname><given-names>MM</given-names></name><name><surname>Pierpont</surname><given-names>B</given-names></name><etal/><article-title>A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents</article-title><source>Hepatology</source><year>2010</year><volume>52</volume><issue>4</issue><fpage>1281</fpage><lpage>1290</lpage><pub-id pub-id-type="doi">10.1002/hep.23832</pub-id><pub-id pub-id-type="pmid">20803499</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Sevastianova</surname><given-names>K</given-names></name><name><surname>Kotronen</surname><given-names>A</given-names></name><name><surname>Gastaldelli</surname><given-names>A</given-names></name><name><surname>Perttil&#x000e4;</surname><given-names>J</given-names></name><name><surname>Hakkarainen</surname><given-names>A</given-names></name><name><surname>Lundbom</surname><given-names>J</given-names></name><name><surname>Suojanen</surname><given-names>L</given-names></name><name><surname>Orho-Melander</surname><given-names>M</given-names></name><name><surname>Lundbom</surname><given-names>N</given-names></name><name><surname>Ferrannini</surname><given-names>E</given-names></name><etal/><article-title>Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans</article-title><source>Am J Clin Nutr</source><year>2011</year><volume>94</volume><issue>1</issue><fpage>104</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.3945/ajcn.111.012369</pub-id><pub-id pub-id-type="pmid">21525193</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Kantartzis</surname><given-names>K</given-names></name><name><surname>Peter</surname><given-names>A</given-names></name><name><surname>Machicao</surname><given-names>F</given-names></name><name><surname>Machann</surname><given-names>J</given-names></name><name><surname>Wagner</surname><given-names>S</given-names></name><name><surname>K&#x000f6;nigsrainer</surname><given-names>I</given-names></name><name><surname>K&#x000f6;nigsrainer</surname><given-names>A</given-names></name><name><surname>Schick</surname><given-names>F</given-names></name><name><surname>Fritsche</surname><given-names>A</given-names></name><name><surname>H&#x000e4;ring</surname><given-names>HU</given-names></name><etal/><article-title>Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene</article-title><source>Diabetes</source><year>2009</year><volume>58</volume><issue>11</issue><fpage>2616</fpage><lpage>2623</lpage><pub-id pub-id-type="doi">10.2337/db09-0279</pub-id><pub-id pub-id-type="pmid">19651814</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>CW</given-names></name><name><surname>Lin</surname><given-names>HY</given-names></name><name><surname>Shin</surname><given-names>SJ</given-names></name><name><surname>Yu</surname><given-names>ML</given-names></name><name><surname>Lin</surname><given-names>ZY</given-names></name><name><surname>Dai</surname><given-names>CY</given-names></name><name><surname>Huang</surname><given-names>JF</given-names></name><name><surname>Chen</surname><given-names>SC</given-names></name><name><surname>Li</surname><given-names>SS</given-names></name><name><surname>Chuang</surname><given-names>WL</given-names></name><article-title>The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population</article-title><source>Liver Int</source><year>2011</year><volume>31</volume><issue>9</issue><fpage>1326</fpage><lpage>1331</lpage><pub-id pub-id-type="doi">10.1111/j.1478-3231.2011.02526.x</pub-id><pub-id pub-id-type="pmid">21745282</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Krawczyk</surname><given-names>M</given-names></name><name><surname>Gruenhage</surname><given-names>F</given-names></name><name><surname>Mahler</surname><given-names>M</given-names></name><name><surname>Tirziu</surname><given-names>S</given-names></name><name><surname>Acalovschi</surname><given-names>M</given-names></name><name><surname>Lammert</surname><given-names>F</given-names></name><article-title>The common adiponutrin variant p.I148M does not confer gallstone risk but affects fasting glucose and triglyceride levels</article-title><source>J Physiol Pharmacol</source><year>2011</year><volume>62</volume><issue>3</issue><fpage>369</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">21893698</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Valenti</surname><given-names>L</given-names></name><name><surname>Rumi</surname><given-names>M</given-names></name><name><surname>Galmozzi</surname><given-names>E</given-names></name><name><surname>Aghemo</surname><given-names>A</given-names></name><name><surname>Del Menico</surname><given-names>B</given-names></name><name><surname>De Nicola</surname><given-names>S</given-names></name><name><surname>Dongiovanni</surname><given-names>P</given-names></name><name><surname>Maggioni</surname><given-names>M</given-names></name><name><surname>Fracanzani</surname><given-names>AL</given-names></name><name><surname>Rametta</surname><given-names>R</given-names></name><etal/><article-title>Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C</article-title><source>Hepatology</source><year>2011</year><volume>53</volume><issue>3</issue><fpage>791</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.1002/hep.24123</pub-id><pub-id pub-id-type="pmid">21319195</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Cai</surname><given-names>T</given-names></name><name><surname>Dufour</surname><given-names>JF</given-names></name><name><surname>Muellhaupt</surname><given-names>B</given-names></name><name><surname>Gerlach</surname><given-names>T</given-names></name><name><surname>Heim</surname><given-names>M</given-names></name><name><surname>Moradpour</surname><given-names>D</given-names></name><name><surname>Cerny</surname><given-names>A</given-names></name><name><surname>Malinverni</surname><given-names>R</given-names></name><name><surname>Kaddai</surname><given-names>V</given-names></name><name><surname>Bochud</surname><given-names>M</given-names></name><etal/><article-title>Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis</article-title><source>J Hepatol</source><year>2011</year><volume>55</volume><issue>3</issue><fpage>529</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2010.12.020</pub-id><pub-id pub-id-type="pmid">21236304</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Tr&#x000e9;po</surname><given-names>E</given-names></name><name><surname>Pradat</surname><given-names>P</given-names></name><name><surname>Potthoff</surname><given-names>A</given-names></name><name><surname>Momozawa</surname><given-names>Y</given-names></name><name><surname>Quertinmont</surname><given-names>E</given-names></name><name><surname>Gustot</surname><given-names>T</given-names></name><name><surname>Lemmers</surname><given-names>A</given-names></name><name><surname>Berthillon</surname><given-names>P</given-names></name><name><surname>Amininejad</surname><given-names>L</given-names></name><name><surname>Chevallier</surname><given-names>M</given-names></name><etal/><article-title>Impact of patatin-like phospholipase-3 (rs738409 C&#x02009;&#x0003e;&#x02009;G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C</article-title><source>Hepatology</source><year>2011</year><volume>54</volume><issue>1</issue><fpage>60</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1002/hep.24350</pub-id><pub-id pub-id-type="pmid">21488075</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Corradini</surname><given-names>SG</given-names></name><name><surname>Burza</surname><given-names>MA</given-names></name><name><surname>Molinaro</surname><given-names>A</given-names></name><name><surname>Romeo</surname><given-names>S</given-names></name><article-title>Patatin-like phospholipase domain containing 3 sequence variant and hepatocellular carcinoma</article-title><source>Hepatology</source><year>2011</year><volume>53</volume><issue>5</issue><fpage>1776</fpage><lpage>1777</lpage><comment>author reply 1777</comment><pub-id pub-id-type="doi">10.1002/hep.24244</pub-id><pub-id pub-id-type="pmid">21351112</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Lagging</surname><given-names>M</given-names></name><name><surname>Langeland</surname><given-names>N</given-names></name><name><surname>Pedersen</surname><given-names>C</given-names></name><name><surname>Farkkila</surname><given-names>M</given-names></name><name><surname>Buhl</surname><given-names>MR</given-names></name><name><surname>Morch</surname><given-names>K</given-names></name><name><surname>Dhillon</surname><given-names>AP</given-names></name><name><surname>Alsio</surname><given-names>A</given-names></name><name><surname>Hellstrand</surname><given-names>K</given-names></name><name><surname>Westin</surname><given-names>J</given-names></name><etal/><article-title>Randomized comparison of 12 or 24&#x02009;weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection</article-title><source>Hepatology</source><year>2008</year><volume>47</volume><issue>6</issue><fpage>1837</fpage><lpage>1845</lpage><pub-id pub-id-type="doi">10.1002/hep.22253</pub-id><pub-id pub-id-type="pmid">18454508</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Bendtsen</surname><given-names>P</given-names></name><name><surname>Karlsson</surname><given-names>N</given-names></name><name><surname>Dalal</surname><given-names>K</given-names></name><name><surname>Nilsen</surname><given-names>P</given-names></name><article-title>Hazardous Drinking Concepts, Limits and Methods: Low Levels of Awareness, Knowledge and Use in the Swedish Population</article-title><source>Alcohol Alcohol</source><year>2011</year><volume>46</volume><issue>5</issue><fpage>638</fpage><lpage>645</lpage><pub-id pub-id-type="pmid">21665870</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>DeFronzo</surname><given-names>RA</given-names></name><name><surname>Tobin</surname><given-names>JD</given-names></name><name><surname>Andres</surname><given-names>R</given-names></name><article-title>Glucose clamp technique: a method for quantifying insulin secretion and resistance</article-title><source>Am J Physiol</source><year>1979</year><volume>237</volume><issue>3</issue><fpage>E214</fpage><lpage>E223</lpage><pub-id pub-id-type="pmid">382871</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Bonora</surname><given-names>E</given-names></name><name><surname>Targher</surname><given-names>G</given-names></name><name><surname>Alberiche</surname><given-names>M</given-names></name><name><surname>Bonadonna</surname><given-names>RC</given-names></name><name><surname>Saggiani</surname><given-names>F</given-names></name><name><surname>Zenere</surname><given-names>MB</given-names></name><name><surname>Monauni</surname><given-names>T</given-names></name><name><surname>Muggeo</surname><given-names>M</given-names></name><article-title>Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity</article-title><source>Diabetes Care</source><year>2000</year><volume>23</volume><issue>1</issue><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.2337/diacare.23.1.57</pub-id><pub-id pub-id-type="pmid">10857969</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Eslam</surname><given-names>M</given-names></name><name><surname>Kawaguchi</surname><given-names>T</given-names></name><name><surname>Del Campo</surname><given-names>JA</given-names></name><name><surname>Sata</surname><given-names>M</given-names></name><name><surname>Khattab</surname><given-names>MA</given-names></name><name><surname>Romero-Gomez</surname><given-names>M</given-names></name><article-title>Use of HOMA-IR in hepatitis C</article-title><source>J Viral Hepat</source><year>2011</year><volume>18</volume><issue>10</issue><fpage>675</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2893.2011.01474.x</pub-id><pub-id pub-id-type="pmid">21914084</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Hosker</surname><given-names>JP</given-names></name><name><surname>Rudenski</surname><given-names>AS</given-names></name><name><surname>Naylor</surname><given-names>BA</given-names></name><name><surname>Treacher</surname><given-names>DF</given-names></name><name><surname>Turner</surname><given-names>RC</given-names></name><article-title>Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man</article-title><source>Diabetologia</source><year>1985</year><volume>28</volume><issue>7</issue><fpage>412</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1007/BF00280883</pub-id><pub-id pub-id-type="pmid">3899825</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Ishak</surname><given-names>K</given-names></name><name><surname>Baptista</surname><given-names>A</given-names></name><name><surname>Bianchi</surname><given-names>L</given-names></name><name><surname>Callea</surname><given-names>F</given-names></name><name><surname>De Groote</surname><given-names>J</given-names></name><name><surname>Gudat</surname><given-names>F</given-names></name><name><surname>Denk</surname><given-names>H</given-names></name><name><surname>Desmet</surname><given-names>V</given-names></name><name><surname>Korb</surname><given-names>G</given-names></name><name><surname>MacSween</surname><given-names>RN</given-names></name><article-title>Histological grading and staging of chronic hepatitis</article-title><source>J Hepatol</source><year>1995</year><volume>22</volume><issue>6</issue><fpage>696</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1016/0168-8278(95)80226-6</pub-id><pub-id pub-id-type="pmid">7560864</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Kollerits</surname><given-names>B</given-names></name><name><surname>Coassin</surname><given-names>S</given-names></name><name><surname>Beckmann</surname><given-names>ND</given-names></name><name><surname>Teumer</surname><given-names>A</given-names></name><name><surname>Kiechl</surname><given-names>S</given-names></name><name><surname>D&#x000f6;ring</surname><given-names>A</given-names></name><name><surname>Kavousi</surname><given-names>M</given-names></name><name><surname>Hunt</surname><given-names>SC</given-names></name><name><surname>Lamina</surname><given-names>C</given-names></name><name><surname>Paulweber</surname><given-names>B</given-names></name><etal/><article-title>Genetic evidence for a role of adiponutrin in the metabolism of apolipoprotein B-containing lipoproteins</article-title><source>Hum Mol Genet</source><year>2009</year><volume>18</volume><issue>23</issue><fpage>4669</fpage><lpage>4676</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddp424</pub-id><pub-id pub-id-type="pmid">19729411</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Romeo</surname><given-names>S</given-names></name><name><surname>Sentinelli</surname><given-names>F</given-names></name><name><surname>Cambuli</surname><given-names>VM</given-names></name><name><surname>Incani</surname><given-names>M</given-names></name><name><surname>Congiu</surname><given-names>T</given-names></name><name><surname>Matta</surname><given-names>V</given-names></name><name><surname>Pilia</surname><given-names>S</given-names></name><name><surname>Huang-Doran</surname><given-names>I</given-names></name><name><surname>Cossu</surname><given-names>E</given-names></name><name><surname>Loche</surname><given-names>S</given-names></name><etal/><article-title>The 148&#x02009;M allele of the PNPLA3 gene is associated with indices of liver damage early in life.</article-title><source>J Hepatol</source><year>2010</year><volume>53</volume><issue>2</issue><fpage>335</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2010.02.034</pub-id><pub-id pub-id-type="pmid">20546964</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Marchesini</surname><given-names>G</given-names></name><name><surname>Brizi</surname><given-names>M</given-names></name><name><surname>Bianchi</surname><given-names>G</given-names></name><name><surname>Tomassetti</surname><given-names>S</given-names></name><name><surname>Bugianesi</surname><given-names>E</given-names></name><name><surname>Lenzi</surname><given-names>M</given-names></name><name><surname>McCullough</surname><given-names>AJ</given-names></name><name><surname>Natale</surname><given-names>S</given-names></name><name><surname>Forlani</surname><given-names>G</given-names></name><name><surname>Melchionda</surname><given-names>N</given-names></name><article-title>Nonalcoholic fatty liver disease: a feature of the metabolic syndrome</article-title><source>Diabetes</source><year>2001</year><volume>50</volume><issue>8</issue><fpage>1844</fpage><lpage>1850</lpage><pub-id pub-id-type="doi">10.2337/diabetes.50.8.1844</pub-id><pub-id pub-id-type="pmid">11473047</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Kotronen</surname><given-names>A</given-names></name><name><surname>Yki-J&#x000e4;rvinen</surname><given-names>H</given-names></name><article-title>Fatty liver: a novel component of the metabolic syndrome</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2008</year><volume>28</volume><issue>1</issue><fpage>27</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">17690317</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Chitturi</surname><given-names>S</given-names></name><name><surname>Abeygunasekera</surname><given-names>S</given-names></name><name><surname>Farrell</surname><given-names>GC</given-names></name><name><surname>Holmes-Walker</surname><given-names>J</given-names></name><name><surname>Hui</surname><given-names>JM</given-names></name><name><surname>Fung</surname><given-names>C</given-names></name><name><surname>Karim</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>R</given-names></name><name><surname>Samarasinghe</surname><given-names>D</given-names></name><name><surname>Liddle</surname><given-names>C</given-names></name><etal/><article-title>NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome</article-title><source>Hepatology</source><year>2002</year><volume>35</volume><issue>2</issue><fpage>373</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1053/jhep.2002.30692</pub-id><pub-id pub-id-type="pmid">11826411</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Marchesini</surname><given-names>G</given-names></name><name><surname>Bugianesi</surname><given-names>E</given-names></name><name><surname>Forlani</surname><given-names>G</given-names></name><name><surname>Cerrelli</surname><given-names>F</given-names></name><name><surname>Lenzi</surname><given-names>M</given-names></name><name><surname>Manini</surname><given-names>R</given-names></name><name><surname>Natale</surname><given-names>S</given-names></name><name><surname>Vanni</surname><given-names>E</given-names></name><name><surname>Villanova</surname><given-names>N</given-names></name><name><surname>Melchionda</surname><given-names>N</given-names></name><etal/><article-title>Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome</article-title><source>Hepatology</source><year>2003</year><volume>37</volume><issue>4</issue><fpage>917</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1053/jhep.2003.50161</pub-id><pub-id pub-id-type="pmid">12668987</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Sepp&#x000e4;l&#x000e4;-Lindroos</surname><given-names>A</given-names></name><name><surname>Vehkavaara</surname><given-names>S</given-names></name><name><surname>H&#x000e4;kkinen</surname><given-names>AM</given-names></name><name><surname>Goto</surname><given-names>T</given-names></name><name><surname>Westerbacka</surname><given-names>J</given-names></name><name><surname>Sovij&#x000e4;rvi</surname><given-names>A</given-names></name><name><surname>Halavaara</surname><given-names>J</given-names></name><name><surname>Yki-J&#x000e4;rvinen</surname><given-names>H</given-names></name><article-title>Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men</article-title><source>J Clin Endocrinol Metab</source><year>2002</year><volume>87</volume><issue>7</issue><fpage>3023</fpage><lpage>3028</lpage><pub-id pub-id-type="doi">10.1210/jc.87.7.3023</pub-id><pub-id pub-id-type="pmid">12107194</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Thomssen</surname><given-names>R</given-names></name><name><surname>Bonk</surname><given-names>S</given-names></name><name><surname>Propfe</surname><given-names>C</given-names></name><name><surname>Heermann</surname><given-names>KH</given-names></name><name><surname>K&#x000f6;chel</surname><given-names>HG</given-names></name><name><surname>Uy</surname><given-names>A</given-names></name><article-title>Association of hepatitis C virus in human sera with beta-lipoprotein</article-title><source>Med Microbiol Immunol</source><year>1992</year><volume>181</volume><issue>5</issue><fpage>293</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1007/BF00198849</pub-id><pub-id pub-id-type="pmid">1335546</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Andr&#x000e9;</surname><given-names>P</given-names></name><name><surname>Komurian-Pradel</surname><given-names>F</given-names></name><name><surname>Deforges</surname><given-names>S</given-names></name><name><surname>Perret</surname><given-names>M</given-names></name><name><surname>Berland</surname><given-names>JL</given-names></name><name><surname>Sodoyer</surname><given-names>M</given-names></name><name><surname>Pol</surname><given-names>S</given-names></name><name><surname>Br&#x000e9;chot</surname><given-names>C</given-names></name><name><surname>Paranhos-Baccal&#x000e0;</surname><given-names>G</given-names></name><name><surname>Lotteau</surname><given-names>V</given-names></name><article-title>Characterization of low- and very-low-density hepatitis C virus RNA-containing particles</article-title><source>J Virol</source><year>2002</year><volume>76</volume><issue>14</issue><fpage>6919</fpage><lpage>6928</lpage><pub-id pub-id-type="doi">10.1128/JVI.76.14.6919-6928.2002</pub-id><pub-id pub-id-type="pmid">12072493</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Owen</surname><given-names>DM</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Gale</surname><given-names>M</given-names></name><name><surname>Ye</surname><given-names>J</given-names></name><article-title>Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins</article-title><source>Proc Natl Acad Sci USA</source><year>2007</year><volume>104</volume><issue>14</issue><fpage>5848</fpage><lpage>5853</lpage><pub-id pub-id-type="doi">10.1073/pnas.0700760104</pub-id><pub-id pub-id-type="pmid">17376867</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>He</surname><given-names>S</given-names></name><name><surname>McPhaul</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>JZ</given-names></name><name><surname>Garuti</surname><given-names>R</given-names></name><name><surname>Kinch</surname><given-names>L</given-names></name><name><surname>Grishin</surname><given-names>NV</given-names></name><name><surname>Cohen</surname><given-names>JC</given-names></name><name><surname>Hobbs</surname><given-names>HH</given-names></name><article-title>A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis</article-title><source>J Biol Chem</source><year>2010</year><volume>285</volume><issue>9</issue><fpage>6706</fpage><lpage>6715</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.064501</pub-id><pub-id pub-id-type="pmid">20034933</pub-id></mixed-citation></ref></ref-list></back></article>